Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer

Faculty Opinions recommendation of Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718357928.793494166 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Hormone Refractory Prostate Cancer ◽

Phase Iii Trial ◽

Hormone Refractory

Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.09.047 ◽

2020 ◽

Vol 106 (2) ◽

pp. 282-290 ◽

Cited By ~ 5

Author(s):

Xin Qi ◽

Hong-Zhen Li ◽

Xian-Shu Gao ◽

Shang-Bin Qin ◽

Min Zhang ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Phase Iii ◽

Postoperative Radiation ◽

Postoperative Radiation Therapy ◽

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032

European Urology ◽

10.1016/j.eururo.2020.09.049 ◽

2021 ◽

Vol 79 (1) ◽

pp. e10-e11

Author(s):

Ethan B. Ludmir ◽

Zachary R. McCaw ◽

Lee-Jen Wei

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Long Term Survivors

Early Neutropenia is Associated with Survival in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) When Treated with Cabazitaxel: an Analysis of Tropic Phase III Trial

Annals of Oncology ◽

10.1093/annonc/mdu336.33 ◽

2014 ◽

Vol 25 ◽

pp. iv271

Author(s):

A. Meisel ◽

S. von Felten ◽

J.S. de Bono ◽

R. De Wit ◽

O. Sartor ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant

PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

European Urology Supplements ◽

10.1016/s1569-9056(19)31321-1 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1824

Author(s):

N.W. Clarke ◽

A.J. Armstrong ◽

A. Thiery-Vuillemin ◽

M. Oya ◽

D. Ye ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Castration Resistant ◽

Line Therapy

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

European Journal of Cancer ◽

10.1016/j.ejca.2013.11.034 ◽

2014 ◽

Vol 50 (5) ◽

pp. 953-962 ◽

Cited By ~ 42

Author(s):

Gwenaelle Gravis ◽

Patricia Marino ◽

Florence Joly ◽

Stéphane Oudard ◽

Franck Priou ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Phase Iii ◽

Self Assessment ◽

PS3 Late breaking Radiation dose-response in prostate cancer: results of a multicenter randomized phase III trial comparing 68 Gy with 78 Gy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)82006-3 ◽

2005 ◽

Vol 3 (4) ◽

pp. 3

Keyword(s):

Prostate Cancer ◽

Radiation Dose ◽

Dose Response ◽

Phase Iii ◽

Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2020-ct014 ◽

2020 ◽

Cited By ~ 5

Author(s):

Christopher J. Sweeney ◽

Silke Gillessen ◽

Dana Rathkopf ◽

Nobuaki Matsubara ◽

Charles Drake ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

BMC Cancer ◽

10.1186/s12885-019-5297-x ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Jeremie Calais ◽

Johannes Czernin ◽

Wolfgang P. Fendler ◽

David Elashoff ◽

Nicholas G. Nickols

Keyword(s):

Prostate Cancer ◽

Molecular Imaging ◽

Salvage Radiotherapy ◽

Phase Iii ◽

Radiotherapy Planning ◽

Phase Iii Trial ◽

Pet Ct ◽

Prospective Phase

Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients

Annals of Oncology ◽

10.1093/annonc/mdw372.07 ◽

2016 ◽

Vol 27 ◽

pp. vi246

Author(s):

C. Vicier ◽

L. Faivre ◽

F. Lesaunier ◽

R. Delva ◽

G. Gravis ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Phase Iii Trial ◽

Two Populations